心脏收缩性调制对于治疗心力衰竭患者的有效性
NingNing Zheng1, YongBing Fu1, MingZhu Xu1
1Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou City, 215006, Jiangsu Province, China.
Cardiovascular engineering and technology
|November 25, 2024
概括
心脏收缩性调制 (CCM) 疗法改善了中国心力衰竭 (HF) 患者的心脏功能. 治疗增强了左心室喷射率 (LVEF) 并在12个月内逆转了心室重塑.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
背景情况:
- 心力衰竭 (HF) 仍然是全球死亡和发病的重要原因.
- 尽管治疗方面取得了进展,但高频管理仍面临着持续的挑战.
研究的目的:
- 评估心脏收缩性调制 (CCM) 在被诊断为心力衰竭的中国患者中的疗效.
- 评估CCM对心脏功能和心室重塑的影响.
主要方法:
- 一项追溯性研究涉及6名患有NYHAII或III级心力衰竭的中国患者.
- 进行了CCM植入,在治疗12个月之前和之后进行了评估.
- 关键的结果指标包括左心室喷射率 (LVEF),左心室终端扩张维度 (LVEDD) 和左心房直径 (LAD).
主要成果:
- 在CCM治疗12个月后,LVEF从27%显著改善到39.67%.
- LVEDD从70.33毫米减少到64.83毫米,表明逆心室重塑.
- LAD从52.83毫米减少到47.00毫米,所有患者都达到NYHA功能类II.
结论:
- 在心力衰竭患者中,CCM疗法显示出提高心脏功能状态的潜力.
- 研究结果表明,CCM可以改善LVEF,并促进逆心室重塑.
- 这项研究为CCM在中国患者队列中的有效性提供了初步证据.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Pathophysiology of Cardiac Performance
566
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
566


